ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Most European countries will miss EU targets on antibacterial use by 2030: historical analysis of European and OECD countries, comparison of community and hospital sectors and forecast to 2040.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Antidepressant drug use in Europe: past consumption, prescribing patterns and forecast until 2030.International journal of clinical pharmacy · 2026Article
- Drug-Resistant Infections in Burn Patients: A One-Year Analysis of Microbiological Trends and Predictive Risk Factors in a Romanian Tertiary Care Centre.Antibiotics (Basel, Switzerland) · 2026Article
- Determinants of prescribing behaviour of antibacterial drugs in Europe and use of appropriate nomenclature in the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- Antimicrobial Consumption in The Community Sector in Poland, 2019-2024: Changes and Challenges.Polish journal of microbiology · 2025Article
- Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- AWaRe classification analysis for European countries with ARIMA forecasts to assess prescribing patterns and 'One Health' targets.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Neural Network-Aided Milk Somatic Cell Count Increase Prediction.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of bacterial resistance threatens the treatment of infections and is closely linked to the consumption of antibacterial drugs. The EU's 'One Health' approach aims to address this issue by requiring Member States to reduce consumption by 20% by 2030. This study analyses antibacterial consumption trends in the total care of European and non-European OECD countries, compares the community and hospital sector, uses ARIMA modelling and correlation analysis to provide long-term forecasts, assesses patterns of consumption and evaluates whether current trends are in line with the EU target. Projections to 2040 show increases for Spain (+36.6%; 30.7 DID), Greece (+31.4%; 37.5 DID), Czechia (+29.7%; 19.4 DID), Bulgaria (+28.3%; 33. 7 DID), Malta (+26.5%; 28.8 DID), Denmark (+25.7%; 19.8 DID), Croatia (+17.4%; 24.9 DID), Italy (+13.7%; 26.3 DID), Germany (+7.6%; 12.6 DID), Australia (+12.4%, 18.2 DID), Canada (+8.0%, 14.8 DID), Chile (+90.1%, 66.7 DID), Costa Rica (+0.4%, 19.7 DID), Japan (+22.7%, 12.8 DID) and Korea (+24.3%, 31.9 DID). Declines are forecast for Belgium (-0.5%; 20.5 DID), Romania (-0.6%; 27.2 DID), Cyprus (-1.0%; 33.2 DID), Luxembourg (-2.2%; 19.8 DID), Norway (-3.4%; 15.1 DID), Latvia (-5.5%; 14.1 DID), Lithuania (-6.4%; 17.5 DID), the Netherlands (-8.4%; 8. 8 DID), Portugal (-10.6%; 16.1 DID), Estonia (-12.1%; 11.2 DID), Slovakia (-16.1%; 16.8 DID), France (-17.7%; 19.8 DID), Hungary (-20.4%; 11.3 DID), Slovenia (-21.9%; 10.5 DID), Finland (-24.8%; 9.7 DID), Iceland (-24.9%; 13.9 DID), Sweden (-30.4%; 7.0 DID) and Israel (-70.7%, 4.7 DID). A significant positive correlation was found between current versus projected consumption levels and changes, highlighting stable prescribing patterns in many countries. Northern and Central Europe maintain low levels of consumption with decreasing trends, whereas Latin America, Eastern and Southern Europe show higher levels with projected increases. Western Europe and Asia shows a mixed pattern, with varying trends of increase and decrease. Alarmingly, only Sweden is projected to meet the 20% reduction target by 2030. Even in the best-case scenario, only a proportion of European countries are projected to meet the target, including Austria, Belgium, Croatia, Cyprus, Finland, France, Greece, Hungary, Italy, Iceland, Lithuania, Luxembourg, Latvia, Portugal, Slovenia, Slovakia and Spain, while 11 countries show no potential for a successful reduction. The reliability of the projections is considered good to moderate. Divergent trends between the community and hospital sectors further complicate the assessment of progress and underline the need for targeted interventions. Current trends suggest that the EU targets are unlikely to be met, highlighting the urgent need to strengthen stewardship programmes. Further research is needed to address other objectives of the 'One Health' approach, including the use of classes of antibacterial drugs and the development of bacterial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.